An Open Parallel Study to Determine the Optimum Dosing Schedule for AS-101 in AIDS/ARC Patients

Inclusion Criteria Concurrent Medication: Allowed: Standard therapy for infections. Acyclovir. Ganciclovir. Allowed only with permission of Wyeth-Ayerst medical monitor: Zidovudine (AZT). Immunomodulators. Specific therapy for malignancies (including Kaposi's sarcoma). Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: Evidence of severe liver dysfunction (serum albumin < 3 g/dl, SGOT or SGPT > 5 x upper limit of normal, prothrombin time > 15 seconds), or gastrointestinal, renal, respiratory, endocrine, hematologic, cardiovascular system abnormalities or psychiatric disorder other than abnormalities secondary to AIDS or AIDS related complex (ARC). Evidence of AIDS-related central nervous system involvement. Disseminated Kaposi's sarcoma. Concurrent Medication: Excluded without permission of Wyeth-Ayerst medical monitor: Zidovudine (AZT). Immunomodulators. Specific therapy for malignancies (including Kaposi's sarcoma). Patients with the following are excluded: Evidence of major system abnormalities other than abnormalities secondary to AIDS or AIDS related complex. Concomitant conditions as specified in Patient Exclusion Co-existing Conditions. Unlikely or unable to comply with the requirements of the protocol. Prior Medication: Excluded within 4 weeks of study entry: Systemic antiviral agents. Immunosuppressive agents. Immune stimulators such as BCG vaccine, isoprinosine, or other immunomodulators. Patients must: Have a diagnosis of AIDS or AIDS related complex (ARC). Demonstrate intolerance or refusal to take zidovudine (AZT). Provide written informed consent.